OOIR: Observatory of International Research

Papers

(The median citation count of Melanoma Research is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Rurality as a predictor of melanoma stage and treatment in Indiana: a retrospective cohort study	55
Immune-related adverse events are associated with therapeutic efficacy of immunotherapy in patients with melanoma brain metastases	36
Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting	29
Clinicopathological demographics of malignant melanomas of the vulva and vagina in Japan	26
Genetic concordance in melanoma: insights from primary tumors and their matched distant metastases	21
Rare immune-related adverse events in a patient with metastatic melanoma: a case report highlighting sarcoidosis-like reactions triggered by immune-checkpoint inhibitors	20
Analysis of circulating tumor DNA during checkpoint inhibition in metastatic melanoma using a tumor-agnostic panel	20
CTLA-4 and TNFRSF1B genetic variants in clinicopathological aspects and outcome of cutaneous melanoma	20
Treatment outcomes in patients with advanced mucosal melanoma in Spain: results from the real-world GEM1801 study	19
Scalp melanoma presents with greater Breslow thickness and higher metastatic burden: analysis of 105 Korean cutaneous head and neck melanoma patients	16
Comprehensive clinical imaging, histopathological analysis and liquid biopsy-based surveillance of human uveal melanoma in a prolonged rabbit xenograft model	15
Assessment of lipid and pigment content in suspicious melanocytic lesions to improve melanoma detection	14
Brain metastases during follow-up of patients with resected cutaneous melanoma	13
Chromosome 1p13.2 gene cluster upregulation in neuroblastoma RAS viral oncogene homolog pathogenic variant melanoma: a potential biomarker axis	13
Do cortisol and psychological distress levels impact the effectiveness of immunotherapy in patients with metastasized melanoma? A pilot study	13
Exploring the clinical significance of specific immune-related adverse events in melanoma patients undergoing immune checkpoint inhibitor therapy	13
Real-world recurrence-free and distant metastasis-free survival in early-stage melanoma: concordance with KEYNOTE-716 trial estimates	12
Outcomes and prognostic factors in melanoma patients with leptomeningeal disease: a retrospective cohort study	12
Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in skin cutaneous melanoma	11
Diffuse large B-cell lymphoma mimicking metastatic melanoma: the importance of biopsies in the era of immune checkpoint inhibitors	11
Twenty-one years of cutaneous melanoma: stage shift, anatomical patterns and diagnostic trends from a Southern European tertiary center	11
Pretreatment CD8+PD-1+ to CD4+PD-1+ ratio is associated with the prognosis of advanced melanoma patients treated with PD-1 inhibitors	10
Cytomegalovirus gastritis as a rare adverse event during combined ipilimumab and nivolumab in a patient with melanoma	10
Clinical and dermoscopical presentation of nivolumab-induced pemphigoid in a metastatic melanoma patient	9
Challenging pigmented lesions in melanoma patients during checkpoint-inhibitors therapy	9

Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis: Erratum	9
Ultraviolet A radiation exposure and melanoma: a review	8
Association of baseline neutrophil-to-lymphocyte ratio and prognosis in melanoma patients treated with PD-1/PD-L1 blockade: a systematic review and meta-analysis	8
Electrical impedance spectroscopy significantly enhances correct biopsy choice for pigmented skin lesions beyond clinical evaluation and dermoscopy	8
Postimmunotherapy antiglial fibrillary acidic protein encephalomyelitis after adjuvant pembrolizumab for melanoma	8
Relationships between survival and real-world recurrence-free survival or distant metastasis-free survival among patients with completely resected stage IIB or IIC melanoma	8
Divergent pathways of melanoma development: evidence from a Southern European cohort	8
Temporal correlation between the first melanoma and the first noncutaneous tumor in CKDN2A genotyped patients	7
Updated meta-analysis on the risk of melanoma associated with phosphodiesterase type 5 inhibitors	7
Multiple melanoma, ichthyosis, and juvenile cataracts in a patient with a germline mutation in CDKN2A: pure coincidence or related association?	7
Immunotherapy for treatment of female genital tract melanoma: National Cancer Database analysis	6
Clostridium difficile infection and immune checkpoint inhibitor–induced colitis in melanoma: 18 cases and a review of the literature	6
Interfering with aggregated α-synuclein in advanced melanoma leads to a major upregulation of MHC class II proteins	6
Regular use of vitamin D supplement is associated with fewer melanoma cases compared to non-use: a cross-sectional study in 498 adult subjects at risk of skin cancers	6
Novel uveal melanoma patient-derived cell line and organoid models show increased treatment resistance compared with commercially available cell lines	6
Exacerbation of Kaposi sarcoma following BRAF/MEK inhibitor therapy in a melanoma patient: a case report and mechanistic insight	6
Safety of tranexamic acid in patients with stage III melanoma undergoing lymph node dissection: a retrospective cohort study	6
Programmed death ligand-1 PET imaging in patients with melanoma: a pilot study	6
Neurologic adverse events associated with BRAF and MEK inhibitor therapy in patients with malignant melanoma: a disproportionality analysis using the Food and Drug Administration Adverse Event Reporti	6
Hemophagocytic lymphohistiocytosis induced by dabrafenib-trametinib in a patient with metastatic melanoma: a case report and pharmacovigilance analysis	5
Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series	5
Immune-related cholecystitis following combination therapy with nivolumab and ipilimumab in a patient with metastatic melanoma: a case report and literature review	5
Variance from published guidelines and changes in temporal trends in the management of cutaneous malignant melanoma: a 5-year update	5
Drug reactions with eosinophilia and systemic symptoms induced by immune checkpoint inhibitors: an international cohort of 13 cases	5
The effect of microRNA-9 overexpression on inhibition of melanoma cancer stem cells tumorigenicity	5
Intratumoural and systemic inflammation as predictors for treatment response in BRAF-mutated melanoma patients under targeted therapies	5
Evaluation of surgical modalities for stage 0 to stage II acral lentiginous melanoma: a National Cancer Database study	5
Trends of adverse event reports associated with BRAF and MEK inhibitors and combinations: a retrospective disproportionality analysis using the FDA adverse event reporting system database from 2012 to	5
Expression and prognostic value of cyclase-associated proteins in cutaneous melanoma	5
Survival and toxicity profile of elderly melanoma patients treated with immune checkpoint inhibitors: a retrospective study from a tertiary care center	4
Re-evaluating melanoma treatment: a comparative look at herpes simplex virus and coxsackievirus oncolytic therapies in advanced melanoma: a meta-analysis of clinical trials	4
Resolution of diffuse cuticular melanosis under immunotherapy in a patient with metastatic melanoma	4
Determinants of adjuvant treatment choice between immunotherapy (immune checkpoint inhibitor) and targeted therapy in resected stage III BRAF V600-mutated cutaneous melanoma: a multicenter observation	4
Screening costs associated with donor selection for fecal microbiota transplantation for treatment of PD-1 refractory melanoma patients	4
Melanoma in the head and neck region: the value of preoperative imaging in melanoma stage I–II	4
DNA methylation of GITR, OX40, 4-1BB, CD27, and CD40 correlates with BAP1 aberrancy and prognosis in uveal melanoma	4
Pseudoprogression in a patient with metastatic melanoma treated with PD-1 and LAG-3 inhibition	4
Schisandrin C suppresses melanoma growth and metastasis through modulation of Rap1-related and phosphatidylinositol 3-kinase/protein kinase B/mechanistic target of rapamycin signaling pathways	4
Pembrolizumab-induced plaque psoriasis successfully treated with risankizumab in a patient with stage IV cutaneous melanoma	4
Bone marrow metastases: a systematic review of a neglected involvement in malignant melanoma	4
Temozolomide monotherapy versus combination therapies in melanoma: a meta-analysis of efficacy and safety	4
Intracranial hemorrhage caused by dabrafenib and trametinib therapy for metastatic melanoma	4
Impact of systemic imaging surveillance on survival from metastatic uveal melanoma	4
Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment	4
Dissecting cellular heterogeneity across two ocular melanoma subtypes by single-cell RNA sequencing	4
Tebentafusp-associated dermatological adverse events in patients with metastatic uveal melanoma: a single-center retrospective cohort study	4
Simultaneous melanomas in the setting of multiple primary melanomas	4
Nectin-4 as predictive biomarker of immune-related adverse event subtypes in adjuvant anti-programmed-death-1 treatment of melanoma	4
Melanoma risk during immunomodulating treatment	4
Neonatal cutaneous melanoma with cutaneous metastasis: a case report and review of literature	3

The London Melanonychia Assessment Tool for the identification of malignant lesions in patients presenting with melanonychia	3
A modern review of uveal melanoma: molecular insights, clinical management, and emerging therapies	3
A rare case of fully regressive melanoma in the absence of metastasis	3
Melanocortin-1 receptor variants and telomerase reverse transcriptase promoter mutations as prognostic biomarkers in stage IIB–IIC melanoma	3
A deep learning-based radiomics model for noninvasive diagnosis of melanoma	3
Efficacy of local ablative therapies in patients with solid tumors treated with immune checkpoint inhibitors and oligoprogression: a single-center analysis	3
Factors to consider in a primary care setting when using convolutional neural network tools for melanoma diagnostics: a retrospective analysis of images and patient characteristics	3
Correlations between inflammatory cytokine levels and degree of pigmentation in acral melanomas	3
Reflectance confocal microscopy versus dermoscopy for the diagnosis of cutaneous melanoma: a head-to-head comparative meta-analysis	3
Assessing melanoma prognosis: the interplay between patient profiles, survival, and BRAF, NRAS, KIT, and TWT mutations in a retrospective multi-study analysis	3
Successful use of rituximab for refractory hemophagocytic lymphohistiocytosis in a melanoma patient treated with targeted therapy	3
Real-world outcomes of different lines and sequences of treatment in BRAF-positive advanced melanoma patients	3
Upregulation of SFTPC gene expression is associated with disease progression and worse survival outcomes in human skin melanomas	3
Relevance of detection of RAF fusion transcripts in pan-negative melanoma in routine practice	3
Combined PDE4+MEK inhibition shows antiproliferative effects in NRAS Q61 mutated melanoma preclinical models	3
Breaking barriers: epithelial–mesenchymal transition role in melanoma invasion and resistance	3
First-time office visit for suspicious skin lesion evaluation as a predictor of high-risk melanoma	3
A retrospective study of clinicopathological and prognostic characteristics in 177 Chinese patients with acral melanoma: heterogeneity based on tumor site	3
Melanoma and pregnant women: a systematic review and meta-analysis	3
Molecular profiling of primary uveal melanoma: results of a Polish cohort	3
Immune checkpoint inhibitor-associated uveitis in metastatic melanoma: case report and literature review	3
The human and animals’ malignant melanoma: comparative tumor models and the role of microbiome in dogs and humans	3
Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma	3
Retrospective comparison of a weight-based dose every 2 weeks with a fixed dose every month: a real-life analysis of nivolumab in the treatment of advanced melanoma	3
Nomograms versus artificial intelligence platforms: which one can better predict sentinel node positivity in melanoma patients?	3
Talimogene laherparepvec monotherapy for head and neck melanoma patients	2
Efficacy of immune checkpoint inhibition in metastatic uveal melanoma: a systematic review and meta-analysis	2
BRCA1-associated protein 1 c.368delG mutation leads to the development of multiple BAPomas and cutaneous melanomas: a novel pathogenic variant in BRCA1-associated protein tumor predisposition syndrome	2
Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma	2
Open-label nonrandomized phase IB study to characterize the safety and recommended dose of tinostamustine in combination with nivolumab in patients with advanced melanoma (ENIgMA)	2
Clinical features of vulvar and vaginal malignant melanomas and the effects of immune checkpoint inhibitors in Japanese patients: a single-center, retrospective cohort study	2
Investigating the causal association between liver condition and melanoma: evidence from the National Health and Nutrition Examination Survey and Mendelian randomization	2
Direct early growth response-1 knockdown decreases melanoma viability independent of mitogen-activated extracellular signal-related kinase inhibition	2
Influence of regression, its extent and tumor-infiltrating lymphocytes on sentinel node status, relapse, and survival in a 10-year retrospective study of melanoma patients	2
Development and validation of prognostic nomogram in pediatric melanoma: a population-based study	2
Clinical response under MEK inhibitor alone in metastatic melanoma with a novel fusion involving the RAF1 gene	2
New technique for in-continuity axillary and supraclavicular lymphadenectomy for advanced metastatic melanoma using intraoperative image guidance: a case report	2
The death rate for melanoma remained unchanged in the USA during the coronavirus disease 2019 pandemic	2
Survivals following discontinuation of PD-1 inhibitor treatment in advanced melanoma patients	2
Description of supportive care and feasibility of physical exercise program to improve quality of life in advanced melanoma patients	2
Expect the unexpected: a saying to bear in mind	2
The role of artificial intelligence and convolutional neural networks in the management of melanoma: a clinical, pathological, and radiological perspective	2
Safety of immune checkpoint inhibitors after proton beam therapy in head and neck mucosal melanoma: a case series	2
Dermatologic surveillance in healthy carriers of CDKN2A and p.E318K MITF germline variants from melanoma-prone families: a 14 years hospital-based experience	2
Anorectal melanoma: systematic review of the current literature of an aggressive type of melanoma	2
Patient-reported outcomes in randomized controlled trials evaluating BRAF inhibitors in patients with cutaneous melanoma: a systematic scoping review of quality of reporting and trial results	2
The importance of mitosis ≥2 in selecting patients with T1 cutaneous melanomas for sentinel lymph node biopsy	2
Epidemiologic characteristics of de novo versus nevus-associated melanoma	2
Psychosocial wellbeing in people with melanoma in-situ: a systematic review	2
Diagnosis and management of concurrent metastatic melanoma and chronic myelomonocytic leukemia	2
CD103 and periplakin are potential biomarkers for response of metastatic melanoma to pembrolizumab	2
The association between dermatologist density and melanoma prognosis using melanoma mortality-incidence ratio	2
Meaningful efficacy measures and trial endpoints in patients with advanced melanoma being considered for adjuvant systemic therapy: a prospective patient survey study	2
Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma	2
Underreporting of acral lentiginous melanoma in studies informing American Joint Committee on Cancer Staging System Guidelines: a review of 150 cited studies	2
Rate of response to immune checkpoint inhibitor therapy in patients with conjunctival melanoma	2
Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors	2
Rapid hyperacute intracranial deterioration following initiation of ipilimumab/nivolumab in BRAF V600E-mutant melanoma of unknown primary with brain metastases after BRAF/MEK inhibitor therapy: a case	2
Impact of gene expression profiling on diagnosis and survival after metastasis in patients with uveal melanoma	2
High dose interleukin-2 in combination with anti-programmed cell death protein 1 to overcome immune checkpoint inhibitor resistance in metastatic melanoma and renal cell carcinoma	2
Exploring the role of epigenetic alterations and non-coding RNAs in melanoma pathogenesis and therapeutic strategies	2
Pregnancy-associated melanoma: characteristics and outcomes from 2002 to 2020	2
High-resolution RNA-sequencing reveals TRIM33::CSDE1 gene fusion in metastasizing vulvar melanoma	2
Immunohistochemistry assessment of tissue neutrophil-to-lymphocyte ratio predicts outcomes in melanoma patients treated with anti-programmed cell death 1 therapy	2
ATF3 regulates CDC42 transcription and influences cytoskeleton remodeling, thus inhibiting the proliferation, migration and invasion of malignant skin melanoma cells	2
pSTAT5 is associated with improved survival in patients with thick or ulcerated primary cutaneous melanoma	2
FGD1 guanine nucleotide exchange factor drives secondary resistance to BRAF inhibition in melanoma	2
LS-007 inhibits melanoma growth via inducing apoptosis and cell cycle arrest and regulating macrophage polarization	2
Vitiligo-like hypopigmentation secondary to adjuvant checkpoint inhibitor therapy in patients with resectable stage III melanoma: a cohort from two tertiary hospitals	2
Melanoma risk prediction based on a polygenic risk score and clinical risk factors	2
Retro- and prospective histologic and immunohistochemical analysis of safety margins following complete excision of less than 1 mm melanomas	2
The effect of COVID-19 on early melanoma detection	2
Relation between dabrafenib plus trametinib-induced pyrexia and age in BRAF V600-mutated metastatic melanoma patients: A post hoc analysis of the real-world ELDERLYMEL study	2
Recent advances in the molecular genetic mechanisms and immune microenvironment of uveal melanoma	2
Combined Mcl-1 and YAP1/TAZ inhibition for treatment of metastatic uveal melanoma	2
Preoperative assessment of cutaneous melanoma thickness by multispectral dermoscopy	2